Name of opportunity: 👀
Novo Nordisk A/S
Flying off the shelves: 💸
Analysts say the diabetes and weight loss market will be worth $100bn by 2030, which means Novo Nordisk A/S could be a great investment. The pharmaceutical company’s product range includes Saxenda, their brand name for liraglutide, a drug similar to Ozempic.
This type of drug has seen enormous popularity over the last year. While often used as a treatment for type 2 diabetes, its use as a weight loss drug has everyone talking. This product has been flying off shelves around the world at such a speed that some countries are running low on supplies, which just goes to show how popular this drug is.
How hot is this investment opportunity? 🔥🔥🔥
Analysts see it as a Buy.
Novo Nordisk A/S has steadily risen in value over the last year.
Analysts predict that Novo Nordisk A/S will increase in value over the next 12 months by 1.98%, from $120.38 to $122.81.
Snapshot of the company: 📸
This is a solid company with a very long history, dating back to the 1920s when Nordisk Insulinlaboratorium started commercially producing insulin.
The value of Novo Nordisk hit a new record high in 2023. Since then, through a $16.5bn deal, Novo Nordisk has acquired three sites previously owned by pharma manufacturers Catalent in order to increase production. It seems they are feeling confident and aiming to scale - suggesting this could be a great time to invest.
Which neme?: 🔍
You can find this stock in the Pharma neme.
